GSK(US:GSK) Di Yi Cai Jing·2025-09-30 15:11Group 1 - The recent CEO changes at Merck and GSK reflect increasing challenges faced by multinational companies [1][3] - GSK appointed Luke Miels as the new CEO, succeeding Emma Walmsley, who has been in the role since 2017 and oversaw an 11% decline in stock price during her tenure [3] - GSK's leadership changes indicate investor concerns about the company's ability to meet its sales target of over £40 billion by 2031 [3][4] Group 2 - Merck announced that Kai Beckman will take over as CEO from Belén Garijo in May 2026, with Garijo remaining in her role in the healthcare division [4][5] - Merck has pursued a differentiated transaction strategy in the pharmaceutical sector, focusing on mid-sized deals valued between €500 million and €600 million rather than large acquisitions [4] - Garijo highlighted the need for supply chain adjustments and strategic flexibility to navigate global trade uncertainties and the complex environment in the Chinese healthcare sector [5]